User:Mr. Ibrahem/Recombinant factor IX
| Clinical data | |
|---|---|
| Trade names | Benefix, Rixubis,[1] Ixinity, Alprolix Idelvion, Rebinyn, others |
| Synonyms | Coagulation factor IX; recombinant factor IX; nonacog alfa; albutrepenonacog alfa; eftrenonacog alfa; nonacog beta pegol |
| AHFS/Drugs.com | Monograph |
Recombinant factor IX, also known as nonacog alfa among others, is a medication used to treat haemophilia B.[1] Specifically it is used to treat and prevent bleeding.[1] Its use improves quality of life.[1] It is given by slow injection into a vein.[1]
Common side effects include fever, cough, pain at the site of injection, and nausea.[2] It may also result in allergic reactions including angioedema, hives, wheezing, or low blood pressure.[3] Antibodies that block its ability to work may also develop.[3] It is a manufactured version of the blood clotting enzyme factor IX, made by recombinant methods.[1]
Recombinant versions were approved for medical use in the United States and Europe in 1997.[2][3][4] It is on the World Health Organization's List of Essential Medicines.[5] In the United Kingdom 1,000 units costs the NHS about £600 as of 2023.[6] This amount in the United States costs about 1,600 USD.[7] There are also versions made from human plasma, but these are associated with risks of infection.[8][6][4]
References
change- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "Factor IX (Recombinant) (Monograph)". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 24 September 2017. Retrieved 12 September 2023.
- ↑ 2.0 2.1 2.2 "BENEFIX (coagulation factor ix- recombinant kit". Dailymed. Archived from the original on 29 January 2023. Retrieved 12 September 2023.
- ↑ 3.0 3.1 3.2 3.3 "BeneFIX EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 17 June 2020. Retrieved 17 June 2020.
- ↑ 4.0 4.1 "Hemophilia: From Plasma to Recombinant Factors". 2008. Archived from the original on 29 May 2023. Retrieved 13 September 2023.
- ↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
- ↑ 6.0 6.1 "Factor IX fraction, dried [Specialist drug] Medicinal forms". BNF. Archived from the original on 13 September 2023. Retrieved 13 September 2023.
- ↑ "Benefix". GoodRx. Retrieved 13 September 2023.
- ↑ "Haemonine 500 / Haemonine 1000". EMC. Archived from the original on 11 April 2022. Retrieved 13 September 2023.